Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.

Stem cells (Dayton, Ohio) - 1 Jan 2003

Ohmine Ken, Nagai Tadashi, Tarumoto Takahisa, Miyoshi Takuji, Muroi Kazuo, Mano Hiroyuki, Komatsu Norio, Takaku Fumimaro, Ozawa Keiya

Abstract excerpt

The BCR/ABL tyrosine kinase inhibitor, imatinib, has shown substantial effects in blast crises of chronic myelogenous leukemia. However, most patients relapse after an initial clinical response, indicating that drug resistance is a major problem for patients being treated with imatinib. In this study, we generated a new imatinib-resistant BCR/ABL-positive cell line, KCL22/SR. The 50% inhibitory concentration of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mitogen-Activated Protein Kinase 3

Share to Mitogen-Activated Protein Kinases

Share to Piperazines

Share to Secondary Prevention

Source

Identifiers

PMID: 12743326
DOI: 10.1634/stemcells.21-3-315

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.PMID 12743326Read ↗

Contribution of BCR–ABL‐independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cellsSemantic proximity Read ↗

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.Semantic proximity Read ↗

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid LeukaemiaSemantic proximity Read ↗

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemiaSemantic proximity Read ↗

Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.Semantic proximity Read ↗

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitorsSemantic proximity Read ↗

MicroRNA profiling in K-562 cells under imatinib treatmentSemantic proximity Read ↗

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cellsSemantic proximity Read ↗

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.Semantic proximity Read ↗

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.Semantic proximity Read ↗

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1Semantic proximity Read ↗

CXCR2 As a Novel Target for Overcoming Resistance to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.